Enterprise Value

208.2M

Cash

384.9M

Avg Qtr Burn

-56.75M

Short % of Float

34.70%

Insider Ownership

17.54%

Institutional Own.

64.47%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Cemacabtagene Ansegedleucel (cema-cel) Details
Cancer, Diffuse large B cell lymphoma

Phase 2

Data readout

Cemacabtagene ansegedleucel, or cema-cel [ALLO-501A (CD19)] Details
Cancer, Non-Hodgkin lymphoma, Diffuse large B cell lymphoma

Phase 2

Data readout

ALLO-647 (Anti-CD52 mAb) Details
Cancer, Diffuse large B cell lymphoma

Phase 2

Update

ALLO-316 (CD70) Details
Renal cell carcinoma, Cancer, Solid tumor/s

Phase 1

Data readout

ALLO-715 (BCMA) Details
Cancer, Multiple myeloma

Phase 1

Update

ALLO-605 (BCMA) Details
Multiple myeloma, Cancer

Phase 1

Update